$ISIS..Q2 notes regarding company outlook for rest of 2014. "For example, we’ll determine if we can replicate the exciting results that we saw in patients with type 2 diabetes. If positive, this would represent a substantial addition to the profile of ISIS-APOCIIIRx. Third, at the end of the year or early next year we plan to report Phase II data from our ISIS-PTP1BRx our novel of insulin sensitizer and ISIS-GCCRx our glucocorticoid receptor drug in patients with type 2 diabetes.
These drugs along with our glucagon receptor drug are part of our substantial portfolio of drugs to treat metabolic disorders including type 2 diabetes. We designed each of these drugs to address a significant unmet medical need in specific segments of the diabetes population. We plan to report full data from our novel anti-thrombotic drug, ISIS-FXIRx later this year at a medical meeting, our top-line Phase II results were certainly very encouraging. And finally, we will continue to mature our pipeline advancing drugs into Phase I and II clinical trials and adding new drugs to the pipeline."
Sheff's Station...All Aboard...Sign Up Here!
